TAAR1 and schizophrenia: In clinical trials, the first tested TAAR1 agonist with 5-HT1A agonist activity Ulotaront showed significant efficacy in treating patients with schizophrenia on both positive and negative symptoms without causing the side effects of existing antipsychotics [140].